Amelioration of cholinergic neurons dysfunction in aged rats depends on the continuous supply of NGF.
The present study was designed to examine whether NGF-induced improvement in morphology of senile basal forebrain cholinergic neurons persist after discontinuation of NGF treatment. Trophic effect of continuous intraventricular infusion of NGF was tested in the 4- and 28 months old male Wistar rats immediately after cessation of NGF and 3 or 6 weeks after termination of treatment. Immunohistochemical procedure for ChAT, TrkA, and p75(NTR) receptor has been applied to identify cholinergic cells in the basal forebrain structures. Using the quantitative image analyzer, morphometric and densitometric parameters of cholinergic cells were measured. In untreated 28-month-old rats a reduction in the number, size and intensity of staining of cholinergic neurons was observed in all basal forebrain structures. NGF significantly improved morphological parameters of ChAT- and TrkA-positive cells in aged rats. In 28-month-old rats tested within 3 and 6 weeks after discontinuation of infusion a renewed progressive deterioration of cholinergic phenotype of basal forebrain neurons was observed when compared with the NGF-treated immediately tested group. The parallel staining for p75(NTR) revealed normal morphology of the basal forebrain neurons, despite of the age of rats or the NGF treatment. Analysis of Nissl stained sections also showed that 28-month-old rats did not display significant losses of neurons in the basal forebrain when compared with the young animals. These findings demonstrate that senile impairment of cholinergic neurons is induced by a loss of cholinergic phenotype rather than an acute degeneration of cell bodies. NGF may be beneficial in enhancing cholinergic neurochemical parameters, but the protective effects seem to be dependent on the continuous supply of NGF.
Niewiadomska
Grazyna
G
Department of Neurophysiology, Nencki Institute, 3 Pasteur St., 02-093 Warsaw, Poland. gwn@nencki.gov.pl
Komorowski
Sebastian
S
Baksalerska-Pazera
Marta
M
D000375:Aging / Q000187:drug effects / Q000502:physiology*; D000465:Algorithms; D000818:Animals; D001342:Autonomic Nervous System Diseases / Q000188:drug therapy / Q000503:physiopathology*; D001479:Basal Ganglia / Q000166:cytology / Q000648:ultrastructure; D001931:Brain Mapping; D002452:Cell Count; D048429:Cell Size / Q000502:physiology; D002795:Choline O-Acetyltransferase / Q000096:biosynthesis / Q000235:genetics; D007150:Immunohistochemistry; D008297:Male; D020932:Nerve Growth Factor / Q000187:drug effects*; D009474:Neurons / Q000187:drug effects / Q000502:physiology* / Q000648:ultrastructure; D010275:Parasympathetic Nervous System / Q000166:cytology / Q000187:drug effects / Q000502:physiology*; D016548:Prosencephalon / Q000166:cytology / Q000187:drug effects / Q000502:physiology; D051381:Rats; D017208:Rats, Wistar; D020800:Receptor, Nerve Growth Factor; D020917:Receptor, trkA / Q000096:biosynthesis / Q000235:genetics; D017475:Receptors, Nerve Growth Factor / Q000096:biosynthesis / Q000235:genetics
D020800:Receptor, Nerve Growth Factor; D017475:Receptors, Nerve Growth Factor; D020932:Nerve Growth Factor; D002795:Choline O-Acetyltransferase; D020917:Receptor, trkA